B of A Securities upgraded Haemonetics (NYSE: HAE) from Neutral to Buy on May 22, 2026. Fintel also cites an analyst price forecast implying 35.40% upside, which is a constructive signal for the stock. The article is limited to analyst sentiment and does not include any operating results or company-specific catalysts.
B of A Securities upgraded Haemonetics (NYSE: HAE) from Neutral to Buy on May 22, 2026. Fintel also cites an analyst price forecast implying 35.40% upside, which is a constructive signal for the stock. The article is limited to analyst sentiment and does not include any operating results or company-specific catalysts.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.38
Ticker Sentiment
